Covid-19 Vaccine Clinical Trial
Official title:
Comparison of Oxidative Stress Parameters, Trace, Element and Quality of Life Levels in Healthy Women Before and After Covid-19 Vaccines
Verified date | February 2021 |
Source | Izmir Bakircay University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
There is no effective treatment method for COVID-19 yet. With vaccination being the most effective approach to control the COVID-19 pandemic, vaccines have been developed with many different methods. One of the vaccines developed, the China-based CoronaVac vaccine (inactivated + aluminum adjuvant vaccine) is a vaccine developed with the inactive method, which is the classical vaccine production method. As a result of Phase 1, Phase 2 and Phase 3 trials, emergency use approval has been given for the CoronaVac vaccine by Turkish Pharmaceuticals and Medical Devices Agency. The clinical picture of COVID-19 can be heterogeneous, ranging from asymptomatic to severe disease, which can be associated with a cytokine storm. In the clinical results of COVID-19, it has been observed that the severity of the disease is lower in women than in men, and the mortality rates are lower in women than in men. A few studies have shown the physiological roles of some vitamins and trace elements in COVID-19. Investigation of free radical levels known to be effective in the development of cardiovascular disease due to oxidative stress is important in determining the risk of cardiovascular complications in the COVID-19 pandemic. In addition, the social isolation rules and quarantine measures applied in the COVID-19 pandemic have caused individuals to be negatively affected physically and psychologically and their quality of life to decrease. Investigating the changes in oxidative stress parameters, trace element and quality of life levels of vaccination in COVID-19 may provide useful information in determining the effects of COVID-19 vaccine. It is planned to include female individuals to be vaccinated in Izmir Bakırcay University Cigli Training and Research Hospital. Within the scope of the study, it was planned to determine the oxidative stress parameters, trace element levels and quality of life levels of the individuals and to compare the values of the data obtained before and after vaccination. After analyzing the data obtained from the research with appropriate statistical methods, the data will be evaluated.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | April 2021 |
Est. primary completion date | March 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 35 Years to 65 Years |
Eligibility | Inclusion Criteria: - Agree to voluntarily participate in the study Exclusion Criteria: - Have been taking trace element supplements for the past 2 weeks - Being pregnant - Body mass index over 40 kg/m2 - Diagnosed with Covid-19 in advance - Not diagnosed with any chronic disease |
Country | Name | City | State |
---|---|---|---|
Turkey | Kadirhan Ozdemir | Izmir |
Lead Sponsor | Collaborator |
---|---|
Izmir Bakircay University | Cigli Regional Training Hospital, Mugla Sitki Koçman University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of the levels of Oxidative Stress Parameter 1 | Oxidative Stress Parameter including Superoxide Dismutase (SOD) will be studied by photometric method in Medical Biochemistry Laboratory. | Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine | |
Primary | Change of the levels of Oxidative Stress Parameter 2 | Oxidative Stress Parameters including Malondialdehyde (MDA) will be studied by photometric method in Medical Biochemistry Laboratory. | Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine | |
Primary | Change of the levels of Oxidative Stress Parameter 3 | Oxidative Stress Parameter including Total Antioxidant Level (TAL) will be studied by photometric method in Medical Biochemistry Laboratory. | Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine | |
Primary | Change of the levels of Oxidative Stress Parameter 4 | Oxidative Stress Parameters including Total Oxidant Level (TOL) will be studied by photometric method in Medical Biochemistry Laboratory. | Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine | |
Primary | Change of the levels serum trace element 1 | Serum trace element including zinc levels will be determined by venous blood samples taken from the participants. Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method. | Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine | |
Primary | Change of the levels serum trace element 2 | Serum trace elements including selenium levels will be determined by venous blood samples taken from the participants. Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method. | Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine | |
Primary | Change of the levels serum trace element 3 | Serum trace element including potassium levels will be determined by venous blood samples taken from the participants. Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method. | Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine | |
Primary | Change of the levels serum trace element 4 | Serum trace element including sodium levels will be determined by venous blood samples taken from the participants. Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method. | Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine | |
Primary | Change of the levels serum trace element 5 | Serum trace elements including calcium levels will be determined by venous blood samples taken from the participants. Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method. | Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine | |
Primary | Change of the levels serum trace element 6 | Serum trace element including magnesium levels will be determined by venous blood samples taken from the participants. Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method. | Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine | |
Primary | Change of the levels serum trace element 7 | Serum trace element including copper levels will be determined by venous blood samples taken from the participants. Serum trace element levels samples will be analyzed using the atomic absorption spectrophotometry (AAS) method. | Immediately before the first dose and 7 days after the second dose of CoronaVac vaccine | |
Primary | Change of the levels of quality of life | SF-36 Quality of Life Scale will be used to determine the quality of life level. The scale that patients can apply themselves and in a short time; It consists of 36 items and 8 subsections. These sections are physical functionality, social functionality, role restrictions due to physical problems, role restrictions due to emotional problems, pain, energy level / vitality / vitality, mental health, and general health perception (40). The last 4 weeks are considered in the evaluation of the scale. The scale gives a separate total score for each subsection. The points obtained from the subsections are not added up. Subdivisions rate health from 0 to 100. While it expresses bad health status as "0 points", it refers to good health status as "100 points". | Immediately before the first dose and 4 weeks later |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05049226 -
Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine
|
Phase 2 | |
Recruiting |
NCT05998824 -
COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease
|
N/A | |
Recruiting |
NCT05097053 -
A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19
|
Phase 4 | |
Active, not recruiting |
NCT05463419 -
A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05293223 -
Phase IIB Study of Recombinant Novel Coronavirus Vaccine
|
Phase 2 | |
Completed |
NCT04691947 -
Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC
|
Phase 1 | |
Completed |
NCT05288231 -
Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand
|
||
Completed |
NCT04546841 -
Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults
|
Phase 1 | |
Recruiting |
NCT04963790 -
Enabling Family Physicians to Reduce Vaccine Hesitancy and Increase Covid-19 Vaccine Uptake
|
N/A | |
Completed |
NCT05216601 -
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19
|
Phase 1 | |
Completed |
NCT04566276 -
ChulaCov19 Vaccine in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04915820 -
Iron and COVID-19 Vaccine Response
|
N/A | |
Completed |
NCT05268679 -
Covid-19 Vaccine Response in Heart Transplant Recipients
|
||
Completed |
NCT04898946 -
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
|
||
Recruiting |
NCT05869968 -
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
|
||
Active, not recruiting |
NCT05197712 -
Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease
|
Phase 1 | |
Recruiting |
NCT05553743 -
Researchers at UC San Diego Are Learning About the Benefits of Human Milk and How it Influences Infant and Child Health
|
||
Active, not recruiting |
NCT05188469 -
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
|
Phase 1/Phase 2 | |
Completed |
NCT04764422 -
Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand
|
Phase 1/Phase 2 | |
Recruiting |
NCT04838080 -
Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo
|
Phase 1 |